98%
921
2 minutes
20
Background: This communication summarizes our single-center experience with the use of anti-IL-1 biologic response modifiers for treating autoimmune and autoinflammatory conditions in children.
Methods: We outline our rationale for the off-label use of anakinra and discuss emerging treatment paradigms that necessitate further research and validation.
Results: Anakinra has enabled personalized treatment, whether used as a single agent on an as-needed basis, as part of a background treatment regimen, or in combination with colchicine. Our data also highlight the significance of anakinra in treating post-infectious inflammatory diseases, demonstrating its high efficacy in novel applications such as rheumatic fever and post-viral arthritis. Canakinumab, on the other hand, has provided long-term remission. Both medications were well-tolerated, with no serious adverse effects reported.
Conclusions: Based on our observations and successful outcomes, we advocate for future collaborative efforts to improve access to anti-IL-1 medications to better manage excessive and harmful inflammation in children.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11430789 | PMC |
http://dx.doi.org/10.3390/children11091146 | DOI Listing |
Oecologia
September 2025
Department of Entomology and Plant Pathology, Auburn University, 301 Funchess Hall, Auburn, AL, 36849, USA.
Understanding changes to local communities brought about by biological invasions is important for conserving biodiversity and maintaining environmental stability. Scale insects (Hemiptera: Coccoidea) are a diverse group of insects well known for their invasion potential and ability to modify local abundance of multiple insect groups. Here, we tested how the presence of crape myrtle bark scale (Acanthococcus lagerstroemiae, CMBS), an invasive felt scale species, seasonally impacted local insect abundance, biodiversity, and community structure on crape myrtle trees.
View Article and Find Full Text PDFJ Hum Hypertens
September 2025
Division of Experimental Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
The Stanley Peart Essay Competition is an annual event run by the British and Irish Hypertension Society to encourage Early Career Researchers to continue the ethos of Sir Stanley Peart. Sir Stanley Peart was a clinician and clinical researcher who made a major contribution to our understanding of blood pressure regulation. He was the first to demonstrate the release of noradrenaline in response to sympathetic nerve stimulation.
View Article and Find Full Text PDFChem Pharm Bull (Tokyo)
September 2025
Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Therapeutic drug monitoring (TDM) is vital for effective optimization of pharmacological treatments. In this study, we engineered a chromatography column that is sensitive to temperature fluctuations, thereby enabling safe and straightforward TDM without relying on organic solvents. Silica beads were modified by applying poly(N-isopropylacrylamide) (PNIPAAm) hydrogels, using a condensation reaction to modify the initiator, followed by radical polymerization to integrate the PNIPAAm hydrogel.
View Article and Find Full Text PDFInj Prev
September 2025
Prehospital Center Region Zealand, Naestved, Denmark.
Background: In situ simulation (ISS) is a form of simulation-based training conducted in participants' working environments to improve clinical performance and system readiness. This study aimed to estimate the incidence of non-satisfactory ISS assessments in the Danish nationwide lifeguard service and to identify associated factors.
Methods: This retrospective study analysed ISS assessment reports completed by lifeguard instructors from 2018 to 2023.
BMJ Open
September 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.
Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.
View Article and Find Full Text PDF